Replies to post #471597 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

You are correct. 128% would be awesome but it’s better than that:

A comparative increase would be 169%
13.2 is 169% of 7.8 if you are talking about OS in recurrent.
DCVax-L OS is 169% of SOC OS for recurrent GBM.

Additionally, the recurrent tails are astonishing. The data represents months or survival becoming years of survival.

[Evaluate]

you wrote:

Getting a 128% improvement in rGBM is AWESOME. This is what I posted about a win in rGBM prior to the presentation

Actually, in my post 470584 the 128% improvement was related to nGBM ... newly diagnosed.
Slide 30: nGBM: DCVax-L improvement over External: 60 months = 13.0% vs 5.7% ... an increase of 128%
(Slide 30 mentions a "Comparative Increase" of 228% ... but I think it makes more sense to refer it as an 128% over the 5.7%)

In my post 470584 I also mentioned .... in regards to rGBM ... recurrent GBM:
Slide 40: rGBM: DCVax-L improvement over External: 30 months = 11.1% vs 5.1% ... an increase of 117%

I agree with you that a 117% improvement in recurrent GBM is still a fantastic result.
In my post I do point out that this 117% improvement relates to a 30-month survival period .... not the same as the above 5-year (60-month) survival period for the newly diagnosed GBM stats.
I do wonder what the current 5-year Survival % is for recurrent GBM, and what the DCVax-L improvement is this 5-year period.

One last point: my post 470584 referenced post 470026 from survivor1x, which included:

Why did the recurrent GBM perform so much better?

I think that nGBM and rGBM ... BOTH ... performed much better with DCVax-L than current SOC.
I do not think that rGBM performed "so much better" than the DCVax-L improvement in nGBM.
I think the nGBM improvement may be a bit superior since it more than doubled the survival for a 60-month term versus the 30-month term survival doubling for the rGBM.